A5062920021- Cancer Immunotherapy and Biomarkers
- Metabolism, Diabetes, and Cancer
- Mast cells and histamine
- Venous Thromboembolism Diagnosis and Management
- Pneumonia and Respiratory Infections
- Ferroptosis and cancer prognosis
- Lung Cancer Treatments and Mutations
- Diabetes Treatment and Management
- Neuroendocrine Tumor Research Advances
- COVID-19 Clinical Research Studies
- Peptidase Inhibition and Analysis
- Multiple and Secondary Primary Cancers
- Chemotherapy-induced cardiotoxicity and mitigation
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Colorectal Cancer Treatments and Studies
- COVID-19 and healthcare impacts
- Neuroscience of respiration and sleep
- Infectious Disease Case Reports and Treatments
- Heparin-Induced Thrombocytopenia and Thrombosis
- Cancer, Lipids, and Metabolism
- Asthma and respiratory diseases
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Lung Cancer Diagnosis and Treatment
- Lung Cancer Research Studies
- Cancer Treatment and Pharmacology
Unity Hospital
2022-2024
Unity Health System
2022-2024
Chung Shan Medical University
2022
Chung Shan Medical University Hospital
2022
Objectives Sodium-glucose cotransporter-2 inhibitors (SGLT2i) reduce heart failure (HF) in at-risk patients and may possess antitumour effects. We examined the effect of SGLT2i on HF mortality among with cancer diabetes. Methods This was a retrospective propensity score-matched cohort study involving adult type 2 diabetes mellitus diagnosed between January 2010 December 2021. The primary outcomes were hospitalisation for incident all-cause mortality. secondary serious adverse events...
Statins are associated with improved survival outcomes in patients receiving immune checkpoint inhibitors (ICIs), but the impact of lipophilic and hydrophilic statin properties on patient is unknown.We aim to investigate if statins clinical ICIs.We conducted a retrospective cohort study at two tertiary referral centers Taiwan comprising ICIs between January 2015 December 2021. We compared comparative effect outcomes. The primary outcome was overall (OS) secondary progression-free (PFS).Among...
Certain angiotensin receptor blockers (ARBs) have peroxisome proliferator-activated receptor-γ (PPAR-γ) activation property, which has been associated with improved programmed cell death ligand 1 blockade and cytotoxic T lymphocyte-mediated antitumor activity.We conducted a retrospective cohort study to investigate the impact of PPAR-γ-activating ARBs on patient survival in patients treated immune checkpoint inhibitors (ICIs) across all types cancers.A total 167 receiving both were included....
e21078 Background: H1-antihistamines are long-used medications for the treatment of allergies. In preclinical studies, antihistamines, particularly those with cationic amphiphilic properties, have been found to anti-tumor effects. observational associated improved survival in patients receiving immune checkpoint inhibitors (ICIs) pan-cancer association studies. However, impact antihistamines on lung cancer is unclear. We aim evaluate effect ICIs. Methods: conducted a retrospective cohort...
Objective Statins have been demonstrated to improve outcomes in patients receiving immune checkpoint blockade (ICB). This study aimed investigate whether the timing of statin administration influences ICB.
Multiple primary lung cancers (MPLCs), characterized by the presence of more than one distinct tumors, may develop either synchronously (simultaneously) or metachronously (after initial cancer treatment). This case describes a rare occurrence three in chronic smoker. After lobectomy for right middle lobe adenocarcinoma (ADC), patient was diagnosed with synchronous small cell carcinoma (SCLC) upper and squamous (SCC) lower lobe. Notably, ADC subsequent were metachronous. Due to her...
Positive pressure ventilation (PPV), both non-invasive and invasive, enhances but can sometimes lead to unexpected hypoxemia. This case report describes an instance of paradoxical hypoxemia after initiating bilevel positive airway (BiPAP) in a 58-year-old female with medical history systemic lupus erythematosus, interstitial lung disease, pulmonary embolism. BiPAP was started, leading improved hypercarbia worsened Further investigation revealed right-to-left interatrial shunt via small...
e24008 Background: Patients with multiple myeloma undergoing proteasome inhibitor therapies face an elevated risk of cardiotoxicity. Existing evidence in the non-cancer population indicates that glucagon-like peptide-1 receptor agonists (GLP1a) can mitigate cardiovascular events. We hypothesize GLP1a may reduce cardiotoxicity patients therapies. Methods: conducted a retrospective, propensity score-matched cohort study by utilizing TriNetX Analytics Network database, which contains...
8031 Background: Osimertinib, a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), is the standard-of-care in EGFR mutation-positive non-small-cell lung cancer (NSCLC) various settings. Osimertinib commonly causes gastrointestinal adverse effects thereby potentially leading to nutritional deficiencies. Therefore, we aim evaluate association between use of osimertinib and deficiencies among patients with NSCLC. Methods: We performed retrospective,...
7548 Background: Immunomodulatory drugs (IMiDs) have been demonstrated to improve clinical outcomes in patients with multiple myeloma (MM), but are associated an elevated risk of thromboembolism. Existing guidelines recommend low-dose direct oral anticoagulants as alternative warfarin for primary thromboprophylaxis MM. However, the data comparing these two therapies limited. We aim compare efficacy and safety apixaban versus MM undergoing IMiD treatment. Methods: conducted a retrospective...
12026 Background: Anthracyclines or human epidermal growth factor receptor 2 (HER-2) inhibitors are associated with the potential for major adverse cardiovascular outcomes (MACE) among patients breast cancer. Diabetes mellitus (DM) further increases risk of MACE. Glucagon-like peptide 1 agonists (GLP1a) have been shown to improve MACE in non-cancer population; however, there no data testing whether GLP1a reduce anthracyclines HER-2 inhibitors. Therefore, we hypothesized that may decrease...
12025 Background: Luteinizing hormone releasing agonists (LHRHa) are the standard of care treatment for prostate cancer but associated with an increased risk cardiotoxicity. Recent studies suggest that sodium glucose cotransporter-2 inhibitors (SGLT2i), a class antidiabetic drugs, reduce cardiovascular events compared to other glucose-lowering agents. We aim investigate potential cardioprotective effect SGLT2i in patients T2DM undergoing LHRHa therapy. Methods: performed retrospective,...
12127 Background: The two most common therapies for the treatment of cancer-associated venous thromboembolism (VTE) are low molecular weight heparin (LMWHs) and direct oral anticoagulants (DOACs). However, there is a paucity data on optimal anticoagulation strategy specifically among patients receiving immune checkpoint inhibitors (ICIs). Therefore, we aimed to evaluate comparable safety efficacy DOACs versus LMWHs in VTE ICIs. Methods: We conducted retrospective, propensity score-matched...
Abstract Introduction Current guidelines recommend limiting the rate of correction in patients with severe hyponatremia to avoid neurologic complications such as osmotic demyelination syndrome (ODS). However, published data have been conflicting. We aimed evaluate association between rapid sodium and ODS hyponatremia. Materials methods searched PubMed, Embase, Scopus, Web Science, Cochrane Central Register Controlled Trials from inception November 2023. The primary outcome was secondary...